Home » Regeneron Wins Expanded Eylea Approval for CRVO
Regeneron Wins Expanded Eylea Approval for CRVO
The FDA Friday approved a second indication for Regeneron Pharmaceuticals’ Eylea to treat macular edema following central retinal vein occlusion (CRVO). The approval was based on two late-stage trials that showed Eylea (aflibercept) significantly improved visual outcomes, Regeneron said.
Drug Industry Daily
Drug Industry Daily
Upcoming Events
-
23Apr
-
25Apr
-
07May
-
14May
-
30May